ID

17219

Description

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00517283

Link

https://clinicaltrials.gov/show/NCT00517283

Keywords

  1. 9/1/16 9/1/16 -
Uploaded on

September 1, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Type 2 Diabetes Mellitus NCT00517283

Eligibility Type 2 Diabetes Mellitus NCT00517283

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects with at least 1 year history of type 2 diabetes mellitus.
Description

Type 2 diabetes mellitus

Data type

boolean

Alias
UMLS CUI [1]
C0011860
subjects controlled by oral antidiabetic agents or diet and exercise demonstrated by a screening hba1c ≥7.0% and ≤10.0%.
Description

HbA1C

Data type

boolean

Alias
UMLS CUI [1]
C0202054
between the body mass index (bmi) of 19 kg/m2 and 40 kg/m2, inclusive.
Description

BMI

Data type

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
within 4 months of the initial dose of study drug, have received a drug that has not received regulatory approval for any indication.
Description

Investigational Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
persons who have previously completed or withdrawn from this study or any other study investigating exenatide.
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
subjects who are using drugs that significantly affect gastrointestinal motility (including acarbose, metoclopramide, and macrolide antibiotics).
Description

drugs affecting gastrointestinal motility

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0017184
subjects who intend to start new concomitant medication during the study, including over-the counter medication, apart from occasional intake of paracetamol or vitamin/mineral supplements. anti-emetic medication may be permitted at the investigator's discretion, except those that affect gastrointestinal motility.
Description

Concomitant medication

Data type

boolean

Alias
UMLS CUI [1]
C2347852
subjects who have used insulin for more than 4 weeks within 3 months prior to screening.
Description

Insulin

Data type

boolean

Alias
UMLS CUI [1]
C0021641
blood donation of more than 500 ml in the last 3 months of screening or any blood donation within the last month.
Description

blood donation

Data type

boolean

Alias
UMLS CUI [1]
C0005794

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00517283

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Type 2 diabetes mellitus
Item
subjects with at least 1 year history of type 2 diabetes mellitus.
boolean
C0011860 (UMLS CUI [1])
HbA1C
Item
subjects controlled by oral antidiabetic agents or diet and exercise demonstrated by a screening hba1c ≥7.0% and ≤10.0%.
boolean
C0202054 (UMLS CUI [1])
BMI
Item
between the body mass index (bmi) of 19 kg/m2 and 40 kg/m2, inclusive.
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Investigational Drugs
Item
within 4 months of the initial dose of study drug, have received a drug that has not received regulatory approval for any indication.
boolean
C0013230 (UMLS CUI [1])
Study Subject Participation Status
Item
persons who have previously completed or withdrawn from this study or any other study investigating exenatide.
boolean
C2348568 (UMLS CUI [1])
drugs affecting gastrointestinal motility
Item
subjects who are using drugs that significantly affect gastrointestinal motility (including acarbose, metoclopramide, and macrolide antibiotics).
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
Concomitant medication
Item
subjects who intend to start new concomitant medication during the study, including over-the counter medication, apart from occasional intake of paracetamol or vitamin/mineral supplements. anti-emetic medication may be permitted at the investigator's discretion, except those that affect gastrointestinal motility.
boolean
C2347852 (UMLS CUI [1])
Insulin
Item
subjects who have used insulin for more than 4 weeks within 3 months prior to screening.
boolean
C0021641 (UMLS CUI [1])
blood donation
Item
blood donation of more than 500 ml in the last 3 months of screening or any blood donation within the last month.
boolean
C0005794 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial